Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 7/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.39 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 3/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004177 | 0.89 | NR1H2 (0.44) | CPT1AMMP13MMP1CPT2CPT1B | |
| SCHEMBL4721307 | 0.86 | TRPC3 (0.49) | MMP13MMP1TRPC3TRPC7GAA | |
| SCHEMBL6004902 | 0.80 | CPT1A (0.43) | CPT1ACPT2CPT1B | |
| SCHEMBL6002772 | 0.80 | TRPC3 (0.44) | CPT1ATMEM97SIGMAR1MMP13MMP1 | |
| SCHEMBL6004476 | 0.78 | ACKR3 (0.41) | CPT1ACPT2CPT1B | |
| SCHEMBL4722163 | 0.77 | MAPK11 (0.49) | TRPC3TRPC7GAA | |
| SCHEMBL4865422 | 0.77 | MAPK14 (0.52) | MMP13MMP1GAARAB9A | |
| SCHEMBL6004618 | 0.76 | CPT1A (0.39) | CPT1A | |
| SCHEMBL4871021 | 0.76 | CPT1A (0.39) | CPT1A | |
| SCHEMBL13576750 | 0.75 | AADAT (0.53) | CPT1ATMEM97SIGMAR1CPT2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | CPT1A 4225/4885TMEM97 2818/4885SIGMAR1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.